<DOC>
	<DOCNO>NCT01199705</DOCNO>
	<brief_summary>The objective study ass efficacy , safety , tolerability , pharmacokinetics subcutaneous immune globulin ( SCIG ; IgPro20 ) subject primary immunodeficiency ( PID ) . In addition , study assess health-related quality life pharmacoeconomic aspect relate treatment IgPro20 .</brief_summary>
	<brief_title>Study Subcutaneous Immune Globulin Patients Requiring IgG Replacement Therapy ( Japan Study )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Diagnosis PID hypo agammaglobulinemia require IgG replacement therapy Intravenous IgG ( IVIG ) therapy regular 3 4week interval stable dose least 3 dos prior sign inform consent Written inform consent Newly diagnose PID , i.e. , subject previously receive immunoglobulin replacement therapy Ongoing serious bacterial infection ( SBIs : pneumonia , bacteremia/septicemia , osteomyelitis/septic arthritis , bacterial meningitis , visceral abscess ) time screen Ongoing history concomitant malignancy lymphoid cell lymphocytic leukemia , nonHodgkin 's lymphoma , immunodeficiency thymoma Allergic severe reaction immunoglobulin blood product record past 3 month time screen Pregnancy nursing mother A positive result screen follow viral marker : human immunodeficiency virus1 ( HIV1 ) , HIV2 , hepatitis C virus , hepatitis B virus Participation study investigational product study within 3 month prior screen Subjects donate blood ( 200 mL within one month 400 mL within 3 month prior screen ) , plan donate blood study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>Primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>